Last price: $959.49 · 52W range $661.85 – $1072.75
Short answer
Should you buy ARGX right now? Stockgaide's AI rates ARGX as
BUY, with a technical score of
90/100 at a last price of $959.49.
The 50-day average is above the 200-day average, and RSI sits at 25.7.
Wall Street's consensus rating is 1.80/5.
Full AI analysis for ARGX
Strategic Conclusion
Recommendation: Buy
Why? ARGX is in a confirmed medium-term uptrend (SMA50 above SMA200) and is trading just above its 50-day average after a sharp pullback. The RSI at 25.7 is deeply oversold, suggesting a technical rebound is likely, while Wall Street’s strong Buy consensus (1.80 mean) and a reasonable P/E of 24 for a commercial-stage biotech add fundamental support.
Ideal profile: Long-term growth investor comfortable with biotech volatility; also suitable for short-term traders looking for an oversold bounce.
Price range: Entry zone $940–$960; first target $1,020; main target $1,072 (52-week high); stop-loss below $900.
Practical action: Buy at current levels or on a dip toward $940. Add on confirmation above $1,000. Reduce if price closes below $900.
1. Recent Price & Momentum
Current price of $959.49 sits about 10.6% below the 52-week high of $1,072.75 and roughly 45% above the 52-week low of $661.85 — upper-middle of the range.
The stock has pulled back sharply from the highs, but remains above both key moving averages, so the broader trend is still constructive.
Short-term scenario: oversold conditions favor a bounce toward $1,000–$1,020; a break below $948 (SMA50) could extend the correction toward $900.
2. Valuation (P/E)
P/E TTM of 24.04 is moderate for a biotech with a commercial product and strong growth pipeline.
Compared to high-growth biotech peers, this multiple is not excessive and suggests the market is pricing in continued execution, but not a bubble.
The valuation is supportive for a Buy, especially if the recent pullback is seen as a better entry point.
3. Technical Analysis
SMA50 ($948.73) is above SMA200 ($849.43) — golden-cross territory, confirming a medium-term uptrend.
RSI(14) at 25.7 is deeply oversold, historically a zone where rebounds are likely.
MACD is below its signal line with negative histogram (-9.21), indicating bearish short-term momentum — this is the main caution flag.
Technical score: 90/100 → BUY, driven by trend strength and oversold rebound potential despite weak MACD.
4. Analyst Consensus
Mean rating 1.80/5 with 22 Buy and 3 Hold — a strong bullish consensus.
Analysts align with the technical score and the golden-cross trend, but the negative MACD suggests near-term caution.
Overall, the fundamental/analyst view and the medium-term technical structure both support a Buy on weakness.
Technical signal details
Rule-based read from price and momentum indicators only — the score behind the AI's recommendation above. Technical score: 90/100 (BUY).
50-day moving average is above the 200-day — medium-term uptrend (golden-cross territory).
MACD is below its signal line — bearish momentum.
RSI at 25.69 — oversold, potential rebound zone.
Wall Street consensus rating of 1.8 — analysts lean Buy.
Stockgaide's AI currently rates ARGX as BUY, with a technical score of 90 out of 100 at a last price of $959.49. This is educational content, not investment advice.
Is ARGX in an uptrend?
ARGX's 50-day moving average (948.73) is above its 200-day moving average (849.43), which points to a medium-term uptrend.
What is ARGX's RSI today?
ARGX has a 14-day RSI of 25.7, which places it in oversold territory (above 70 is overbought, below 30 is oversold).
What do analysts say about ARGX?
Wall Street analysts covering ARGX have a consensus rating of 1.80 out of 5 (1 = Strong Buy), meaning they lean Buy — 22 Buy · 3 Hold · 0 Sell.
Where is ARGX trading in its 52-week range?
ARGX last traded at $959.49, against a 52-week range of $661.85 to $1072.75 — about 72% of the way up that range.
Get the full AI analysis of ARGX
Price targets, fundamentals deep-dive and an AI-written report — free, no signup.